Global Oral Proteins and Peptides 麻豆原创 Growth 2024-2030

Publication ID:

LPI01247173

Publication Date:

January 4, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Oral Proteins and Peptides market size was valued at US$ 2449 million in 2023. With growing demand in downstream market, the Oral Proteins and Peptides is forecast to a readjusted size of US$ 6769.8 million by 2030 with a CAGR of 15.6% during review period.
The research report highlights the growth potential of the global Oral Proteins and Peptides market. Oral Proteins and Peptides are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Oral Proteins and Peptides. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Oral Proteins and Peptides market.
Polypeptide and protein drugs refer to the biological drugs of polypeptide and protein substances used for prevention,treatment and diagnosis.Polypeptide is a compound formed by linking 伪-amino acids together with a peptide chain,and it is also an intermediate product of proteolysis.N polypeptide chains are entangled in a certain spatial structure to form a protein.The hydrolysis of macromolecular proteins produces polypeptides.Such drugs are biochemical preparations and have relatively strict requirements on storage and transportation environment.The Oral Proteins and Peptides industry can be broken down into several segments, Linaclotide, Insulin, Plecanatide, Cyclosporine, Octreotide, etc.Across the world, the major players cover Ironwood & Allergan (AbbVie), Novo Nordisk, Synergy Pharmaceuticals (Salix), Novartis, Chiasma (Amryt Pharma), etc.

Ironwood & Allergan is one of the most important global manufacturers of oral proteins and peptides, other key manufacturers include Novo Nordisk. North America is the largest market, occupied for over 60%. In terms of type, insulin is the largest segment, with a share of over 60%. And in terms of application, gastric & digestive disorders and bone diseases segment holds the most share.
Key Features:
The report on Oral Proteins and Peptides market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Oral Proteins and Peptides market. It may include historical data, market segmentation by Type (e.g., Linaclotide, Insulin), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Oral Proteins and Peptides market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Oral Proteins and Peptides market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Oral Proteins and Peptides industry. This include advancements in Oral Proteins and Peptides technology, Oral Proteins and Peptides new entrants, Oral Proteins and Peptides new investment, and other innovations that are shaping the future of Oral Proteins and Peptides.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Oral Proteins and Peptides market. It includes factors influencing customer ' purchasing decisions, preferences for Oral Proteins and Peptides product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Oral Proteins and Peptides market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Oral Proteins and Peptides market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Oral Proteins and Peptides market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Oral Proteins and Peptides industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Oral Proteins and Peptides market.
麻豆原创 Segmentation:
Oral Proteins and Peptides market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Linaclotide
Insulin
Plecanatide
Cyclosporine
Octreotide
Segmentation by application
Gastric & Digestive Disorders
Bone Diseases
Diabetes
Hormonal Disorders
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ironwood & Allergan
Novo Nordisk
Synergy Pharmaceuticals 锛圫alix锛�
Novartis
Chiasma (Amryt Pharma)
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oral Proteins and Peptides market?
What factors are driving Oral Proteins and Peptides market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Proteins and Peptides market opportunities vary by end market size?
How does Oral Proteins and Peptides break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Oral Proteins and Peptides Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Oral Proteins and Peptides by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Oral Proteins and Peptides by Country/Region, 2019, 2023 & 2030
2.2 Oral Proteins and Peptides Segment by Type
2.2.1 Linaclotide
2.2.2 Insulin
2.2.3 Plecanatide
2.2.4 Cyclosporine
2.2.5 Octreotide
2.3 Oral Proteins and Peptides Sales by Type
2.3.1 Global Oral Proteins and Peptides Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Oral Proteins and Peptides Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Oral Proteins and Peptides Sale Price by Type (2019-2024)
2.4 Oral Proteins and Peptides Segment by Application
2.4.1 Gastric & Digestive Disorders
2.4.2 Bone Diseases
2.4.3 Diabetes
2.4.4 Hormonal Disorders
2.5 Oral Proteins and Peptides Sales by Application
2.5.1 Global Oral Proteins and Peptides Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Oral Proteins and Peptides Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Oral Proteins and Peptides Sale Price by Application (2019-2024)
3 Global Oral Proteins and Peptides by Company
3.1 Global Oral Proteins and Peptides Breakdown Data by Company
3.1.1 Global Oral Proteins and Peptides Annual Sales by Company (2019-2024)
3.1.2 Global Oral Proteins and Peptides Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Oral Proteins and Peptides Annual Revenue by Company (2019-2024)
3.2.1 Global Oral Proteins and Peptides Revenue by Company (2019-2024)
3.2.2 Global Oral Proteins and Peptides Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Oral Proteins and Peptides Sale Price by Company
3.4 Key Manufacturers Oral Proteins and Peptides Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Proteins and Peptides Product Location Distribution
3.4.2 Players Oral Proteins and Peptides Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oral Proteins and Peptides by Geographic Region
4.1 World Historic Oral Proteins and Peptides 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Oral Proteins and Peptides Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Oral Proteins and Peptides Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Oral Proteins and Peptides 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Oral Proteins and Peptides Annual Sales by Country/Region (2019-2024)
4.2.2 Global Oral Proteins and Peptides Annual Revenue by Country/Region (2019-2024)
4.3 Americas Oral Proteins and Peptides Sales Growth
4.4 APAC Oral Proteins and Peptides Sales Growth
4.5 Europe Oral Proteins and Peptides Sales Growth
4.6 Middle East & Africa Oral Proteins and Peptides Sales Growth
5 Americas
5.1 Americas Oral Proteins and Peptides Sales by Country
5.1.1 Americas Oral Proteins and Peptides Sales by Country (2019-2024)
5.1.2 Americas Oral Proteins and Peptides Revenue by Country (2019-2024)
5.2 Americas Oral Proteins and Peptides Sales by Type
5.3 Americas Oral Proteins and Peptides Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Proteins and Peptides Sales by Region
6.1.1 APAC Oral Proteins and Peptides Sales by Region (2019-2024)
6.1.2 APAC Oral Proteins and Peptides Revenue by Region (2019-2024)
6.2 APAC Oral Proteins and Peptides Sales by Type
6.3 APAC Oral Proteins and Peptides Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oral Proteins and Peptides by Country
7.1.1 Europe Oral Proteins and Peptides Sales by Country (2019-2024)
7.1.2 Europe Oral Proteins and Peptides Revenue by Country (2019-2024)
7.2 Europe Oral Proteins and Peptides Sales by Type
7.3 Europe Oral Proteins and Peptides Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Proteins and Peptides by Country
8.1.1 Middle East & Africa Oral Proteins and Peptides Sales by Country (2019-2024)
8.1.2 Middle East & Africa Oral Proteins and Peptides Revenue by Country (2019-2024)
8.2 Middle East & Africa Oral Proteins and Peptides Sales by Type
8.3 Middle East & Africa Oral Proteins and Peptides Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Proteins and Peptides
10.3 Manufacturing Process Analysis of Oral Proteins and Peptides
10.4 Industry Chain Structure of Oral Proteins and Peptides
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Proteins and Peptides Distributors
11.3 Oral Proteins and Peptides Customer
12 World Forecast Review for Oral Proteins and Peptides by Geographic Region
12.1 Global Oral Proteins and Peptides 麻豆原创 Size Forecast by Region
12.1.1 Global Oral Proteins and Peptides Forecast by Region (2025-2030)
12.1.2 Global Oral Proteins and Peptides Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oral Proteins and Peptides Forecast by Type
12.7 Global Oral Proteins and Peptides Forecast by Application
13 Key Players Analysis
13.1 Ironwood & Allergan
13.1.1 Ironwood & Allergan Company Information
13.1.2 Ironwood & Allergan Oral Proteins and Peptides Product Portfolios and Specifications
13.1.3 Ironwood & Allergan Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Ironwood & Allergan Main Business Overview
13.1.5 Ironwood & Allergan Latest Developments
13.2 Novo Nordisk
13.2.1 Novo Nordisk Company Information
13.2.2 Novo Nordisk Oral Proteins and Peptides Product Portfolios and Specifications
13.2.3 Novo Nordisk Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novo Nordisk Main Business Overview
13.2.5 Novo Nordisk Latest Developments
13.3 Synergy Pharmaceuticals 锛圫alix锛�
13.3.1 Synergy Pharmaceuticals 锛圫alix锛� Company Information
13.3.2 Synergy Pharmaceuticals 锛圫alix锛� Oral Proteins and Peptides Product Portfolios and Specifications
13.3.3 Synergy Pharmaceuticals 锛圫alix锛� Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Synergy Pharmaceuticals 锛圫alix锛� Main Business Overview
13.3.5 Synergy Pharmaceuticals 锛圫alix锛� Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Oral Proteins and Peptides Product Portfolios and Specifications
13.4.3 Novartis Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Chiasma (Amryt Pharma)
13.5.1 Chiasma (Amryt Pharma) Company Information
13.5.2 Chiasma (Amryt Pharma) Oral Proteins and Peptides Product Portfolios and Specifications
13.5.3 Chiasma (Amryt Pharma) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Chiasma (Amryt Pharma) Main Business Overview
13.5.5 Chiasma (Amryt Pharma) Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.